Merofic-O 300mg ER-Tablet contains Faropenem, a broad-spectrum oral carbapenem antibiotic effective against a wide range of Gram-positive and Gram-negative bacterial infections. The extended-release formulation ensures sustained plasma concentrations, enhancing therapeutic efficacy and improving patient compliance by reducing dosing frequency. Faropenem exerts its bactericidal action by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins, leading to cell lysis and death. Merofic-O 300mg ER is indicated for the treatment of respiratory tract infections, urinary tract infections, skin and soft tissue infections, and other susceptible bacterial infections. It demonstrates efficacy against pathogens resistant to other beta-lactam antibiotics, including certain strains producing beta-lactamase enzymes. The drug is generally well-tolerated, with a safety profile consistent with carbapenem antibiotics; common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal pain. Caution is advised in patients with a history of hypersensitivity to beta-lactams. Dosage adjustments may be necessary in renal impairment. Merofic-O 300mg ER-Tablet should be prescribed based on susceptibility testing and clinical judgment to minimize the development of resistance. It is contraindicated in patients with known hypersensitivity to Faropenem or any component of the formulation.